Please assess the completion status of the following clinical trial:

Trial Title: Mortality Reduction After Oral Azithromycin: Mortality Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Communities~* The community location in target district.~* The community leader consents to participation in the trial~* The community's estimated population is between 200-2,000 people.~* The community is not in an urban area.~Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census.~Exclusion Criteria:~Individuals~- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 60 Months
- Healthy Volunteers: t

Study Arms:
- Biannual mass oral azithromycin (Type: ACTIVE_COMPARATOR): Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.~In Niger during year 3, all communities will be offered azithroymcin.
- Biannual mass oral placebo (Type: PLACEBO_COMPARATOR): Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~In Niger during year 3, all communities will be offered azithroymcin.

Based on this trial design, predict the completion outcome and termination type (if applicable).